Company Encyclopedia
View More
name
Alpha Teknova
TKNO.US
Alpha Teknova, Inc. produces critical reagents for the discovery, development, and commercialization of novel therapies, vaccines, and molecular diagnostics in the United States and internationally. The company’ primary products include pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It provides lab essentials which provides chemical formulations for use in biological research and drug discovery; and clinical solutions, a custom product used in the development and production of protein therapies, gene therapies, mRNA vaccines, and diagnostic kits.
770.89 B
TKNO.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
C
Life Sciences Tools and ServicesIndustry
Industry Ranking38/60
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-22.79%E
    • Profit Margin-45.78%E
    • Gross Margin30.67%C
  • Growth ScoreC
    • Revenue YoY9.50%B
    • Net Profit YoY42.49%B
    • Total Assets YoY-13.27%E
    • Net Assets YoY-16.75%E
  • Cash ScoreC
    • Cash Flow Margin-218.45%D
    • OCF YoY9.50%B
  • Operating ScoreD
    • Turnover0.34D
  • Debt ScoreB
    • Gearing Ratio32.50%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Alpha Teknova Among 3 Penny Stocks Worth Noting

    The article highlights the potential of penny stocks amidst a mixed U.S. stock market, focusing on Alpha Teknova, Marqeta, and Hyliion Holdings. Alpha Teknova, with a market cap of $230.18M, is noted for its strong cash position and projected revenue growth. Marqeta, valued at $2.09B, leverages its cloud-based API platform for growth, while Hyliion Holdings, with a market cap of $299.16M, focuses on clean energy technology despite high volatility and lack of revenue. The article emphasizes the opportunities and risks associated with these stocks.

    Simplywall·
    US
    HYLN
    -1.01%
    US
    TKNO
    -2.69%
    Simplywall·
    US
    HYLN
    -1.01%
    US
    TKNO
    -2.69%

    Alpha Teknova (NASDAQ:TKNO) Issues Quarterly Earnings Results

    Alpha Teknova (NASDAQ:TKNO) reported quarterly earnings of ($0.08) EPS, with a negative net margin of 55.24% and a negative return on equity of 26.51%. The company updated its FY 2025 guidance. Shares fell 2.8% to $4.81, with a market cap of $257.38 million. Analysts have mixed ratings, with an average rating of "Moderate Buy" and a price target of $10.00. Hedge funds have increased their stakes in the company, indicating some institutional interest despite the recent earnings miss.

    Market Beat·
    US
    TKNO
    -2.69%
    Market Beat·
    US
    TKNO
    -2.69%

    Alpha Teknova | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 10.45 M

    LB filings·
    US
    TKNO
    -2.69%
    LB filings·
    US
    TKNO
    -2.69%

    Positive Outlook for Alpha Teknova: Consistent Revenue Growth and Strategic Expense Management Drive Buy Rating

    William Blair analyst Matt Larew has reiterated a Buy rating on Alpha Teknova (TKNO) stock, citing consistent revenue growth and effective expense management. The company reported a 9% revenue increase for the fifth consecutive quarter, while maintaining operating expenses below $8 million for six quarters. Positive trends in biotech funding and the pharmaceutical sector enhance Teknova's outlook, aiming for adjusted EBITDA breakeven by 2026. TD Cowen also supports a Buy rating with a $7.00 price target.

    Tip Ranks·
    US
    TKNO
    -2.69%
    Tip Ranks·
    US
    TKNO
    -2.69%

    Alpha Teknova’s Strong Performance and Growth Potential Justifies Buy Rating Despite Market Adjustments

    Alpha Teknova has received a Buy rating from analyst Brendan Smith of TD Cowen, with a price target of $7.00. The rating is based on strong Q3 financial results, particularly in the Lab Essentials segment, which offset challenges in Clinical Solutions. The company’s diversified revenue streams provide stability, and a potential recovery in biotech funding could enhance growth. Despite a price target adjustment from $10 to $7 due to market conditions, the outlook remains positive, with an expected 10% revenue growth by FY26.

    Tip Ranks·
    US
    TKNO
    -2.69%
    Tip Ranks·
    US
    TKNO
    -2.69%
    © 2025 Longbridge｜Disclaimer